Research programme - lysosomal storage diseases therapeutics - Vtesse/NCATS

Drug Profile

Research programme - lysosomal storage diseases therapeutics - Vtesse/NCATS

Alternative Names: Cyclodextrin - Vtesse/NCATS; Delta-tocopherol - Vtesse/NCATS; Niemann-Pick disease therapeutics - Vtesse/NCATS; Tocopherol derivatives - Vtesse/NCATS

Latest Information Update: 05 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer National Center for Advancing Translational Sciences; National Institutes of Health (USA)
  • Class Cyclodextrins; Tocopherols
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Lysosomal-storage diseases

Most Recent Events

  • 03 Apr 2017 Vtesse has been acquired by Sucampo Pharmaceuticals
  • 20 Jan 2015 Early research in Lysosomal storage diseases in USA (unspecified route)
  • 07 Jan 2015 Cyclodextrin, delta-tocopherol, and derivatives of tocopherol licensed to Vtesse worldwide for the treatment of Niemann-Pick disease type C
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top